More in detail, five out of seven are based on the administration of paclitaxel albumin-stabilized nanoparticle formulations, alone or in combination with other compounds, in taxol resistant patients with metastatic breast cancer[152], in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer[153,154], in advanced gastric cancer[155] and in platinum-resistant recurrent ovarian cancer[156]. Here, ALB is linked to ovarian cancer.